OraSure Technologies
OraSure Technologies' revenue fell 38.1% to $115 million in fiscal 2025. Its operating margin was −62.6%, down from −15.2% a year earlier. Free cash flow was −$53 million, against $24 million a year earlier. It paid out $15 million in dividends and buybacks. The diluted share count fell 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What OraSure Technologies does
OraSure Technologies (OTI) makes rapid diagnostic tests and devices for collecting samples such as saliva and urine. Its tests detect HIV, hepatitis C, syphilis, sickle cell disease and COVID-19, and give results at the point of care. It sells them in the United States and abroad to clinical laboratories, hospitals, clinics, community groups, public health bodies, distributors, government agencies and doctors' offices. Its HIV and COVID-19 tests are also sold to consumers over the counter in the U.S., and its HIV and hepatitis C products are sold as self-tests in several other countries.
It has two main lines of business: diagnostics products, and sample management solutions. Sample management products are used by clinical laboratories, direct-to-consumer laboratories, researchers, drug companies and animal health companies. Its principal products include the OraQuick HIV tests and the InteliSwab COVID-19 test. It also sells to the U.S. government and says it expects InteliSwab revenue to keep declining.
In November 2025 it bought BioMedomics, whose SickleSCAN test is sold outside the U.S. In December 2025 it asked the FDA to clear a molecular self-test for chlamydia and gonorrhea and an at-home urine collection device. As of December 31, 2025, it had 500 full-time employees.
Its biggest risks, as it describes them
- Falling sales of its InteliSwab COVID-19 test, which it expects to continue.
- Reliance on U.S. government funding and customers, with audits, contract limits and ordering that can change.
- Increasing competition from other diagnostic test and sample collection providers.
- Some products depend on a sole-source supplier, and manufacturing problems could stop deliveries.
- Its results may suffer if customers do not keep adopting oral fluid testing and collection products.
Income statement
From fiscal 2016 to 2023, earnings per share grew 10.9% a year and net income 15.4% a year, as new shares raised the share count by 32% and diluted each share's earnings. OraSure Technologies then lost money in fiscal 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 153 | 111 | 290 | 268 | 199 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.4x | 4.7x | 9.8x | 9.9x | 6.6x |
| Quick ratio | 3.6x | 3.3x | 8.6x | 8.9x | 5.8x |
Cash flow
Projections
Project OraSure Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What OraSure Technologies says to expect
- Full year 2027: total revenue growth
The Company expects to see an acceleration of year-over-year growth in total revenues for the full year 2027 as compared to the full year 2026.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 4 insiders bought $456,495 of OraSure Technologies shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 14, 2026 | Steven Kyle BoydDirector | Bought | 25,000 | $2.99 | $74,750 | Form 4 |
| May 13, 2026 | Steven Kyle BoydDirector | Bought | 25,000 | $3.02 | $75,500 | Form 4 |
| May 12, 2026 | Steven Kyle BoydDirector | Bought | 25,000 | $2.98 | $74,500 | Form 4 |
| Mar 20, 2026 | Manner Carrie EglintonPresident & CEO, Director | Bought plan | 32,300 | $2.93 | $94,639 | Form 4 |
| Mar 13, 2026 | Manner Carrie EglintonPresident & CEO, Director | Bought plan | 22,022 | $3.00 | $66,066 | Form 4 |
| Mar 13, 2026 | Kenneth J McGrathChief Financial Officer | Bought plan | 22,021 | $3.00 | $66,063 | Form 4 |
| Nov 28, 2025 | Nancy J GaglianoDirector | Bought | 2,100 | $2.37 | $4,977 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 38.1% | −41.5% | −84.4% |
| Altman Z'' | 13.27 | 9.22 | 6.76 |
| Accruals ratio | −19.0% | −9.7% | −4.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put OraSure Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| OraSure Technologies | FY25 | −38.1% | −62.6% | −46.3% | — | — | — | |
| Anika Therapeutics | FY25 | −5.9% | −9.8% | 3.9% | — | — | — | Compare |
| Outset Medical | FY25 | 5.1% | −55.8% | −39.4% | −88.0% | — | 6 | Compare |
| Owlet | FY25 | 35.4% | −7.8% | −10.5% | — | — | 5 | Compare |
| Sanara MedTech | FY25 | 19.0% | 7.1% | 2.1% | 13.0% | 2.6x | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 128 | 167 | 182 | 155 | 172 | 234 | 388 | 406 | 186 | 115 |
| Revenue growth | 7.1% | 30.3% | 8.8% | −14.9% | 11.1% | 36.1% | 65.8% | 4.6% | −54.2% | −38.1% |
| Gross profit | 88 | 99 | 114 | 95 | 102 | 118 | 148 | 172 | 79 | 48 |
| Research and development | 10 | 13 | 16 | 20 | 31 | 34 | 36 | 34 | 26 | 42 |
| Operating income | 20 | 40 | 28 | 19 | −5 | −10 | −22 | 33 | −28 | −72 |
| Net income | 20 | 31 | 20 | 17 | −15 | −23 | −17 | 54 | −20 | −69 |
| Diluted EPS (US$) | 0.35 | 0.51 | 0.33 | 0.27 | — | −0.32 | −0.24 | 0.72 | −0.26 | −0.94 |
| Diluted shares (millions) | 56 | 61 | 62 | 62 | 68 | 72 | 72 | 74 | 74 | 74 |
| Cash flow | ||||||||||
| Cash from operations | 25 | 28 | 39 | 10 | 6 | −35 | −47 | 142 | 27 | −49 |
| Capital expenditure | 4 | 4 | 6 | 9 | 27 | 22 | 7 | 6 | 4 | 4 |
| Free cash flow | 20 | 24 | 33 | 0 | −21 | −57 | −54 | 136 | 24 | −53 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 3 | 1 | 4 | 4 | 2 | 2 | 2 | 0 | 0 | 15 |
| Acquisitions | 0 | 0 | 0 | 24 | 3 | 0 | 0 | 0 | 5 | 4 |
| Stock-based compensation | 6 | 7 | 15 | 4 | 7 | 8 | 12 | 11 | 12 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 119 | 154 | 157 | 156 | 209 | 153 | 111 | 290 | 268 | 199 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 208 | 296 | 316 | 349 | 454 | 461 | 444 | 483 | 480 | 403 |
| Total liabilities | 22 | 38 | 32 | 42 | 56 | 80 | 80 | 52 | 69 | 62 |
| Shareholders' equity | 186 | 258 | 283 | 307 | 399 | 380 | 364 | 431 | 410 | 341 |
| Margins and ratios | ||||||||||
| Gross margin | 68.7% | 59.2% | 62.5% | 61.2% | 59.3% | 50.3% | 38.3% | 42.3% | 42.7% | 41.9% |
| Operating margin | 15.8% | 24.1% | 15.6% | 12.0% | −3.0% | −4.3% | −5.7% | 8.1% | −15.2% | −62.6% |
| Net margin | 15.4% | 18.5% | 11.2% | 10.8% | −8.7% | −9.8% | −4.4% | 13.2% | −10.5% | −59.8% |
| Free cash flow margin | 15.8% | 14.3% | 18.0% | 0.3% | −12.2% | −24.5% | −13.9% | 33.5% | 12.7% | −46.3% |
| Rule of 40 (growth + FCF margin) | 22.9% | 44.6% | 26.8% | −14.6% | −1.1% | 11.6% | 51.9% | 38.1% | −41.5% | −84.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | 11.4% | 13.9% | 7.5% | 5.6% | −4.2% | −5.9% | −4.6% | 13.5% | −4.6% | −18.3% |
| Return on assets | 9.9% | 12.3% | 6.7% | 5.0% | −3.7% | −5.0% | −3.8% | 11.6% | −4.0% | −15.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |